LCN2 and metabolic syndrome: Besides simple ECG recordings [40], novel biomarkers reflecting diabetes, heart failure and the metabolic syndrome, such as natriuretic peptides and neutrophil gelatinase-associated lipocalin (NGAL) [41–46] may reveal the potential to improve risk-stratification in terms of prediction of all-cause and cardiovascular mortality in high-risk patients with ventricular tachyarrhythmias in future [45, 46].